Budde, K <br/><br/>
Reduced-exposure cyclosporine is safe and efficacious in de novo renal transplant recipients treated with enteric-coated mycophenolic acid and basiliximab.  [electronic resource] 

 -  Clinical nephrology  Mar 2007 
 - 164-75 p.  digital 
<br/><br/> Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0301-0430 
<br/><br/><label>Standard No.: </label>10.5414/cnp67164  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Acute Disease<br/>Adolescent<br/>Adult<br/>Aged<br/>Antibodies, Monoclonal--administration & dosage<br/>Basiliximab<br/>Belgium--epidemiology<br/>Biopsy<br/>Creatinine--blood<br/>Cyclosporine--administration & dosage<br/>Dose-Response Relationship, Drug<br/>Drug Administration Routes<br/>Drug Therapy, Combination<br/>Emulsions<br/>Enzyme Inhibitors--administration & dosage<br/>Female<br/>Follow-Up Studies<br/>Germany--epidemiology<br/>Graft Rejection--blood<br/>Humans<br/>Immunosuppressive Agents--administration & dosage<br/>Kidney Transplantation--adverse effects<br/>Male<br/>Middle Aged<br/>Mycophenolic Acid--administration & dosage<br/>Recombinant Fusion Proteins--administration & dosage<br/>Survival Rate<br/>Tablets, Enteric-Coated<br/>Time Factors<br/>Treatment Outcome